Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
about
Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.Targeting the PD-1 pathway in pediatric solid tumors and brain tumors.The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression.An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma.Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.Detection of ABCB5 tumour antigen-specific CD8+ T cells in melanoma patients and implications for immunotherapy.The dawn of vaccines for cancer prevention.Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections.Current Strategies to Enhance Anti-Tumour Immunity.Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers.BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients.Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.Ilixadencel - an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration.Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma
P2860
Q38643300-A8A40079-D52B-4067-991F-FB96D01FF4E3Q38704554-271FE025-96A8-404F-B1B5-F24FEB396EDCQ38819982-715F45DB-2962-4AF4-9732-2DCE90CF4F3CQ46142906-5CE08749-DE0E-49AD-81DC-39C94E10AABAQ47161735-5DF9121E-A480-47C8-B29B-7C591E783165Q47233994-BB3F5D0F-AA41-42C7-8446-4C2F856E0340Q47865137-964F6444-45EF-45E8-9930-CE4A1FE93C92Q49566629-4BFEA308-3D1A-4EB3-93B2-98CCEC708741Q50335281-5947467C-C762-4FAC-ADE3-A1EF274EA6B1Q52344613-1DE689D0-4441-4A56-81CF-A1A06750B5E8Q52592731-AE28E378-BF2E-4DC6-B5F0-6B0601D8B334Q53697395-F38F9088-9306-4D8D-B025-D9DC52D18700Q55060215-3A1C6D81-0E34-4617-95B1-423BE8A7B9CFQ55380684-77DE7E10-C192-4C51-A57B-21759A6617BAQ57794659-93143BBE-6AD9-45C4-837D-4C6EFDB21528
P2860
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
@ast
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
@en
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
@nl
type
label
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
@ast
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
@en
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
@nl
prefLabel
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
@ast
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
@en
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
@nl
P2093
P2860
P356
P1433
P1476
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
@en
P2093
Charlotte Blanc
Delphine Giusti
Marie Anson
Soumaya Karaki
Stephane Oudard
P2860
P356
10.3390/VACCINES4040037
P407
P50
P577
2016-11-03T00:00:00Z